Business ❯ Finance ❯ Investments

Pharmaceuticals

Eli Lilly Stock Market Novo Nordisk Acquisitions Pfizer Drug Development Stock Performance Indian Pharma Stocks Clinical Trials Tariffs

Eli Lilly Spends $3.8 Billion to Build Vaccine Business

Management says the purchases are a long-term hedge funded by strong GLP-1 profits that will not meaningfully change near-term earnings.

Novo Nordisk Lifts 2026 Outlook as Wegovy Pill Powers Big Q1 Beat

Novo Nordisk Lifts 2026 Outlook on Surging Wegovy Pill Uptake

Cardinal Health Lifts 2026 Profit Outlook After Q3 Beat Despite Sales Miss

AbbVie Tops Q1 and Raises 2026 Outlook as Skyrizi and Rinvoq Offset Humira Decline

Amneal to Acquire Kashiv BioSciences to Expand in Biosimilars

Law Firms Seek Ultragenyx Investors to Lead Securities Class Actions After OI Trial Miss

Cantor Raises Innoviva Target to $32 After Q4 Beat on China XacDuro Builds

Eli Lilly Tightens GLP-1 Grip, Guides Up to $83 Billion for 2026

Zydus, Aurobindo Report Q3 Profit Growth as U.S. Sales Climb and Labour-Code Charges Weigh

Mankind Pharma’s Q3 Profit Climbs on Chronic-Drug Demand as Shares Slide on Margin Concerns

Regeneron Beats Q4 and Charts 2026 Catalysts With FDA Decisions and Phase III Push

Lilly Signs Up to $1.12 Billion Gene-Editing Pact to Tackle Hearing Loss

Novo Nordisk Leans on Wegovy’s New MASH Indication and First Oral Obesity Pill to Rebound in 2026

FDA Approves Vanda’s Nereus, First New Motion Sickness Treatment in Over 40 Years

Bristol Myers Enters 2026 With Eliquis Medicaid Pact, Opdivo Qvantig Rollout, and Divergent Analyst Views

FDA Approves Novo Nordisk’s Wegovy Pill, First Oral GLP-1

BioMarin to Acquire Amicus for $4.8 Billion in Cash

Novo Nordisk Presses India Expansion and Higher-Dose Push as Analyst Views Diverge

Yahoo Finance Highlights Merck and Bristol Myers as Value Plays Outside the GLP-1 Surge